Sino Biological Launches Antigens for 2026-2027 Influenza Vaccine Strains Following WHO Recommendations

The World Health Organization has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting two key developments: the continued spread of A (H3N2) subclade K and the growing circulation of new B/Victoria lineage strains. In rapid response, Sino Biological has launched a comprehensive panel of antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains to accelerate influenza vaccine development.

Since its identification in August 2025, H3N2 subclade K has become the dominant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO's selection of A/Darwin/1454/2025 as the new H3N2 reference viruses. The H1N1 component has been updated to A/Missouri/11/2025. Alongside H3N2, influenza B activity is rising sharply, with the proportion of B/Victoria lineage viruses recently increasing from 6% to over 20% in regions such as Hong Kong and the U.S. These trends led WHO to recommend B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains for the upcoming season.

To support global influenza vaccine research and development, Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains, spanning key viral antigens including Hemagglutinin, Neuraminidase, and Nucleoprotein. These include H1N1 reagents for A/Missouri/11/2025, H3N2 subclade K proteins aligned with A/Darwin/1454/2025, and influenza B reagents in development for B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025. The company provides stable HA trimers with high purity and SEC-MALS validation that maintain native conformation for accurate immune characterization.

This announcement matters because timely access to high-quality antigens is critical for vaccine developers to respond effectively to evolving influenza strains. The WHO's identification of strains with enhanced immune escape capabilities creates urgency for vaccine manufacturers to update their formulations. Sino Biological's rapid deployment of these reagents enables researchers to begin vaccine development immediately rather than waiting months to produce their own antigens. The company's comprehensive portfolio covering all recommended strains provides a complete toolkit for vaccine development, potentially shortening the timeline from strain identification to vaccine availability.

The implications extend beyond the 2026-2027 season, as this demonstrates an improved response system for emerging influenza threats. By providing standardized, high-quality reagents immediately following WHO recommendations, Sino Biological helps create a more efficient global vaccine development pipeline. This is particularly important given the enhanced immune escape properties of the H3N2 subclade K strain, which could reduce the effectiveness of existing vaccines. The growing circulation of B/Victoria lineage strains also represents a significant shift in influenza epidemiology that requires updated vaccine components. Researchers can access these critical tools through Sino Biological's website to advance their vaccine development programs.